BioTime Announces Appointment of General Counsel
May 22 2019 - 8:00AM
Business Wire
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage
biotechnology company developing cellular therapies for unmet
medical needs, today announced that it has appointed Chase C.
Leavitt as BioTime’s General Counsel and Corporate Secretary.
“We’re extremely fortunate to have Chase join us and bring his
extensive public company experience as well as a strong track
record to the role of general counsel,” stated Brian M. Culley,
Chief Executive Officer of BioTime. “Chase’s diverse industry
experience including SEC compliance, corporate governance,
strategic transactions and mergers and acquisitions will be
instrumental as BioTime continues to execute on its clinical and
operational plans.”
Prior to joining BioTime, Mr. Leavitt served as Vice President
of Legal Affairs of Tang Capital Management, LLC, a life
sciences-focused investment company, and its affiliate Odonate
Therapeutics, Inc., a publicly traded pharmaceutical company, from
June 2018 to May 2019. From May 2017 to May 2018, Mr. Leavitt
served as the Deputy General Counsel of Switch, Inc., a publicly
traded technology company, and previously served as its Associate
General Counsel from July 2014 to May 2017. From 2007 to 2014, Mr.
Leavitt was a corporate attorney at Latham & Watkins LLP, where
his practice focused on public company representation, mergers and
acquisitions and capital markets, serving life sciences and
technology companies. Mr. Leavitt received a B.S. in Business
Administration and a J.D. from the University of Southern
California and is admitted to practice law by the State Bar of
California.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company developing new
cellular therapies for unmet medical needs. BioTime’s programs are
based on its proprietary cell-based therapy platform and associated
development and manufacturing capabilities. With this platform
BioTime develops and manufactures specialized,
terminally-differentiated human cells from its pluripotent and
progenitor cell starting materials. These differentiated cells are
developed either to replace or support cells that are dysfunctional
or absent due to degenerative disease or traumatic injury, or
administered as a means of helping the body mount an effective
immune response to cancer. BioTime’s clinical assets include (i)
OpRegen®, a retinal pigment epithelium transplant therapy in Phase
I/IIa development for the treatment of dry age-related macular
degeneration, the leading cause of blindness in the developed
world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in
Phase I/IIa development for the treatment of acute spinal cord
injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of
antigen-presenting dendritic cells currently in Phase I development
for the treatment of non-small cell lung cancer. For more
information, please visit www.biotimeinc.com or follow the Company
on Twitter @BioTimeBTX.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190522005219/en/
BioTime Inc. IRIoana C. Honeir@biotimeinc.com(510)
871-4188
Solebury Trout IRGitanjali Jain
OgawaGogawa@troutgroup.com(646) 378-2949
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Sep 2023 to Sep 2024